Atypical mycobacteria (209 strains) were examined for susceptibility to rifampin by the proportion method by using Middlebrook 7H-10 agar. All strains of Mycobacterium kansasii and tap-water scotochromogens were inhibited by 0.25 to 1 Ag of the drug per ml. Seventy-six per cent of M. scrofulaceum and 61 % of M. intracellulare strains were susceptible to 4 Ag/ml or less; 5% of the former and 8% of the latter were resistant to 16 ,ug/ml. All strains of M. gastri and M. triviale and most strains of M. terrae were sensitive to 1 to 4,g/ml. Two strains of M. borstelense were both inhibited by 8 Ag/ml. Nearly all strains of M.
fortuitum were resistant to the drug. The results of this study suggest that rifampin may be a valuable agent for the treatment of many atypical mycobacterial infections.
Rifampin is a semisynthetic orally administered derivative of rifamycin SV. In addition to its activity against gram-positive cocci (with the exception of enterococcus), Neisseria meningitidis and N. gonorrhoeae (1, 4) , it is highly effective in vitro (3, 8-10, 12, 14) and in vivo (5, 7, 13, 15) against Mycobacterium tuberculosis. However, in vitro determinations of the sensitivity of atypical mycobacteria to this drug have yielded variable and somewhat conflicting results (3, (8) (9) (10) 12) . This disparity may have been related, in some instances, to the small number of strains examined and to differences in methodology. The present investigation was undertaken for two purposes:
(i) to reexamine the effects of rifampin on atypical mycobacteria by the proportion method of Cannetti et al. (2) All of the mycobacteria were cultured on LUwenstein medium for 4 to 6 weeks. Subcultures of each strain were then made in 7H-9 broth containing Tween 80; all were shaken daily for 1 min. After 7 to 10 days of incubation at 37 C (3 to 5 days for "rapid growers"), each culture was diluted with sterile water to a turbidity approximating the McFarland 1 standard (1 mg of bacterial mass per ml) and then diluted 1:100 and 1:10,000 in sterile water. Three drops (Pasteur pipette) of each dilution were spread on quadrants of agar containing different concentrations of rifampin and on control quadrants that were drug-free. The plates were sealed in polyethylene bags and incubated at 37 C for 2 to 4 weeks (7 to 10 days for "rapid growers"); at this time, heavy growth of the organisms was present on the agar to which no antibiotic had been added.
The number of viable units in the inoculum was indicated by the number of colonies that developed on drug-free media. A strain was considered resistant to a particular concentration of rifampin when the number of colonies detected was equal to or greater than 1 % of the viable units present in the inoculum.
RESULTS
The inhibitory concentrations of rifampin and the cumulative percentages of all of the mycobac- terial strains susceptible to the drug are presented in Table 1 and Fig. 1 4 Mg/ml; the other six were resistant to 16 Mg/ml. Only two strains of M. borstelense were examined; both were inhibited by 8 ,g/ml. DISCUSSION Rifampin is the 3-(4-methyl-1-piperazinylimminomethyl) derivative of rifamycin SV. It is well absorbed when given orally; a single dose of 600 mg taken on an empty stomach produces peak blood levels of 7 to 10 Mg per ml in 0.5 to 2 hr (4, 6, 14) . The drug is excreted primarily in the bile; it has a relatively long half-life.
Rifampin is highly active against M. tuberculosis. All strains of this organism, whether sensitive or resistant to other tuberculostatic agents, are inhibited in vitro by low concentrations of this antibiotic (3, 8-10, 14) . The rate of spontaneously occurring resistant mutants is about 1 in 107 organisms (10, 14) . This drug has proved very effective in the therapy of advanced or multidrug-resistant pulmonary tuberculosis, or both, when used together with other tuberculostatic agents, especially ethambutol (5, 7, 13, 15) . Resistance to rifampin may develop in a single-step fashion during treatment; this usually occurs when it is used without a satisfactory companion drug (5, 13) .
Determination of the sensitivity of atypical mycobacteria to rifampin in vitro has yielded variable and somewhat conflicting results (3, (8) (9) (10) 12) . For example, strains of M. kansasii were reported by Clark and Wallace (3) to be resistant and by others (8) (9) (10) 12) to be sensitive to this agent. Reasons for this discrepancy include: (i) the small number of strains examined by some investigators, (ii) failure to speciate organisms within Runyon groups II to IV in certain instances, (iii) differences in media (liquid versus solid) used for determination of drug susceptibility, (iv) the use of inocula of varying size, and (v) differences in the criterion of resistance employed by investigators. In the present investigation, a large number of strains identified by species were studied. Susceptibility determinations were performed by the proportion method, which eliminates problems related to the inoculum size.
The criterion for resistance suggested by Canetti et al. (2) (5, 7, 13, 15) , it could prove a valuable adjunct to drug regimens used in the management of atypical mycobacterial infections due to susceptible strains.
